Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia

European Journal of Haematology

Volumn 82, Issue 6, 2009, Pages 454-457

  Daar, Shahina ^a   Pathare, Anil ^a   Nick, Hanspeter ^b   Kriemler Krahn, Ulrike ^b   Hmissi, Abdel ^b   Habr, Dany ^b   Taher, Ali ^c  

^a SULTAN QABOOS UNIVERSITY   (Oman)

^b NOVARTIS PHARMA AG   (Switzerland)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

thalassaemia; Deferasirox; Labile plasma iron; Oral; Pharmacokinetic

Indexed keywords

DEFERASIROX; FERRITIN; IRON;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT DURATION;

ADOLESCENT; ADULT; BENZOIC ACIDS; BETA-THALASSEMIA; CHILD; FEMALE; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MALE; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 65349110837     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01204.x     Document Type: Article

References (10)

1. Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 1978 40 : 255 63.
2. Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 2000 23 : 185 92.
3. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005 18 : 277 87.
4. al Refaie FN, Sheppard LN, Nortey P, Wonke B, Hoffbrand AV. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol 1995 89 : 403 8.
5. Porter JB. Deferoxamine pharmacokinetics. Semin Hematol 2001 38 (Suppl. 1 63 8.
6. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003 361 : 1597 602.
7. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006 91 : 873 80.
8. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003 102 : 2670 7.
9. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994 331 : 574 8.
10. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997 89 : 739 61.